Prediction versus prevention of sudden cardiac death

Lancet

Volumn 367, Issue 9523, 2006, Pages 1639-1641

  Viskin, Sami ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; DEFIBRILLATOR; ELECTROCARDIOGRAPHY MONITORING; HEART DISEASE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART RATE VARIABILITY; HEART VENTRICLE TACHYCARDIA; HIGH RISK POPULATION; HOLTER MONITORING; HUMAN; MORTALITY; PREDICTION; PRIORITY JOURNAL; REVASCULARIZATION; SENSITIVITY AND SPECIFICITY; SINUS ARRHYTHMIA; SUDDEN DEATH; SURVIVAL TIME;

EID: 33646576532     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68712-6     Document Type: Note

References (18)

1. Buxton A., Lee K., Fisher J., Josephson M., Prystowsky E., and Hafley G. Randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med 341 (1999) 1882-1890
2. Moss A., Hall W., Cannom D., et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 335 (1996) 1933-1940
3. Buxton A. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction ≤30% should receive an implantable cardioverter-defibrillator. Circulation 111 (2005) 2537-2549
4. Moss A., Zareba W., Hall W., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 (2002) 877-883
5. Buxton A., Lee K., DiCarlo L., et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med 342 (2000) 1937-1945
6. Kron J., Herre J., Renfroe E., et al. Lead- and device-related complications in the antiarrhythmics versus implantable defibrillators trial. Am Heart J 141 (2001) 92-98
7. Bauer A., Kantelhardt J., Petra Barthel P., et al. Deceleration capacity of heart rate as a predictor of mortality after myocardial infarction: cohort study. Lancet 367 (2006) 1674-1681
8. La Rovere M., Bigger Jr. J., Marcus F., and for the ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. Lancet 351 (1998) 478-484
9. Barthel P., Schneider R., Bauer A., et al. Risk stratification after acute myocardial infarction by heart rate turbulence. Circulation 108 (2003) 1221-1226
10. Copie X., Hnatkova K., Staunton A., Fei L., Camm A., and Malik M. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction: results of a two-year follow-up study. J Am Coll Cardiol 27 (1996) 270-276
11. Huikuri H., Tapanainen J., Lindgren K., et al. Prediction of sudden cardiac death after myocardial infarction in the beta-blocking era. J Am Coll Cardiol 42 (2003) 652-658
12. el-Sherif N., Denes P., Katz R., et al. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period. J Am Coll Cardiol 25 (1995) 908-914
13. Bigger Jr. J. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med 337 (1997) 1569-1575
14. Hohnloser S., Kuck K., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 351 (2004) 2481-2488
15. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 (1999) 2001-2007
16. Solomon S., Zelenkofske S., McMurray J., et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352 (2005) 2581-2588
17. Moss A. Implantable cardioverter defibrillator therapy: the sickest patients benefit the most. Circulation 101 (2000) 1638-1640
18. Wilber D., Zareba W., Hall W., et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation 109 (2004) 1082-1084